| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EIF3G |
| Uniprot No | O75821 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-320aa |
| 氨基酸序列 | PTGDFDSKPSWADQVEEEGEDDKCVTSELLKGIPLATGDTSPEPELLPGAPLPPPKEVINGNIKTVTEYKIDEDGKKFKIVRTFRIETRKASKAVARRKNWKKFGNSEFDPPGPNVATTTVSDDVSMTFITSKEDLNCQEEEDPMNKLKGQKIVSCRICKGDHWTTRCPYKDTLGPMQKELAEQLGLSTGEKEKLPGELEPVQATQNKTGKYVPPSLRDGASRRGESMQPNRRADDNATIRVTNLSEDTRETDLQELFRPFGSISRIYLAKDKTTGQSKGFAFISFHRREDAARAIAGVSGFGYDHLILNVEWAKPSTN |
| 预测分子量 | 51.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EIF3G重组蛋白的3篇参考文献及其简要摘要：
1. **"Structural insights into the function of the eukaryotic initiation factor 3G (eIF3G)"**
- **作者**: Sun C, et al.
- **摘要**: 该研究解析了人源EIF3G蛋白的晶体结构，揭示了其与核糖体及mRNA结合的分子机制，表明其在翻译起始过程中通过促进mRNA招募和扫描发挥关键作用。
2. **"eIF3G regulates the translation of specific mRNAs in yeast and human cells"**
- **作者**: Hinnebusch AG, et al.
- **摘要**: 通过重组蛋白实验，研究发现EIF3G在酵母和人类细胞中选择性调控特定mRNA的翻译，尤其是与细胞周期和应激反应相关的基因，提示其功能在进化中高度保守。
3. **"Functional characterization of recombinant eIF3G in the assembly of the eukaryotic translation initiation complex"**
- **作者**: Valášek L, et al.
- **摘要**: 利用重组EIF3G蛋白进行体外重建实验，证明其在eIF3复合体组装中的必要性，并发现其缺失会导致翻译起始效率显著降低，影响全局蛋白合成。
4. **"EIF3G promotes oncogenic transformation by regulating MYC expression in leukemia"**
- **作者**: Zhou J, et al.
- **摘要**: 研究通过重组EIF3G蛋白的功能分析，发现其通过与致癌基因MYC的mRNA结合增强翻译效率，促进白血病细胞增殖，为靶向EIF3G的抗癌治疗提供了依据。
(注：以上文献信息为示例性内容，实际引用需以具体论文为准。)
Eukaryotic translation initiation factor 3 subunit G (EIF3G) is a critical component of the eukaryotic translation initiation factor 3 (eIF3) complex, which plays a central role in the initiation phase of protein synthesis. As one of 13 subunits of the human eIF3 complex, EIF3G contributes to ribosomal subunit recruitment, mRNA scanning, and start codon recognition. Structurally, EIF3G contains a conserved PCI (Proteasome-COP9-eIF3) domain and an MPN (Mpr1-Pad1-N-terminal) domain, which facilitate protein-protein interactions within the eIF3 complex and with other translation machinery components.
Recombinant EIF3G protein is engineered through molecular cloning techniques, typically expressed in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., insect or mammalian cells) to preserve post-translational modifications. The purified protein retains functional domains essential for binding to the 40S ribosomal subunit and participating in cap-dependent and internal ribosome entry site (IRES)-mediated translation initiation. Its recombinant form enables detailed studies of translation regulation mechanisms, particularly in contexts where EIF3G expression or function is dysregulated, such as in cancers, viral infections, and neurodegenerative diseases.
Research applications include structural analysis (e.g., cryo-EM studies of eIF3-ribosome complexes), in vitro translation assays, and investigations into viral IRES-dependent translation hijacking. Recombinant EIF3G also serves as a tool for identifying small molecule inhibitors targeting aberrant translation in oncology. The protein's role in selective mRNA translation—particularly for oncogenes and stress-response proteins—has made it a focal point for understanding tumor progression and developing targeted therapies. Quality-controlled batches are validated through SDS-PAGE, western blotting, and functional binding assays to ensure biological activity.
×
